Median Technologies Reports 93.3% Sensitivity for Lung Cancer Screening Device in Clinical Study

Median Technologies will present study results supporting eyonis LCS lung cancer screening software at CHEST on October 19, 2026, in Phoenix. The 2,163-patient study suggests the device reduces false positives and missed cancers, supporting more consistent clinical decisions. The software received FDA 510(k) clearance in February 2026; its US commercial rollout is supported by engagement with lung cancer screening providers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief via (Ref. ID: 20261014903907) on October 14, 2026, and is solely responsible for the information contained therein. (C)